Abbott Laboratories Settles Preterm-Infant Formula Litigation for ~$670M

What Happened
On August 20, 2026, Abbott Laboratories announced it entered into agreements to resolve the Gill lawsuit and necrotizing enterocolitis (NEC) claims for approximately 2,000 additional infants for an aggregate payment of about $670 million. The Gill case arose from a July 2024 Missouri jury award of $495 million (which Abbott appealed); the Missouri Court of Appeals affirmed that verdict in May 2026. Abbott says these agreements are a compromise of disputed claims and not an admission of liability, and the company continues to assert the safety and supporting science of its products.

Key Details

• Aggregate settlement amount: approximately $670 million (announced Aug 20, 2026).
• Gill case background: $495 million jury award in July 2024; Missouri Court of Appeals affirmed in May 2026; continuing appeal alternatives included paying ~ $600 million (judgment plus accrued interest) or further appeal.
• Scope: Agreements resolve the Gill case plus NEC claims asserted on behalf of ~2,000 additional infants.
• Remaining litigation: After these agreements, about 1,700 lawsuits remain pending in federal and state courts involving claims on behalf of ~12,700 individual infants.

Why It Matters
This settlement reduces a major near-term legal uncertainty by resolving a high-profile verdict and thousands of related claims, which could affect Abbott’s cash outflows and legal exposure. The company stresses the payments are compromises, not admissions of liability, and significant litigation remains (1,700 suits, ~12,700 infants). Investors should watch Abbott’s forthcoming financial disclosures for how the company records the settlement, any impact on reserves or cash, and updates on remaining litigation.